Oragenics, Inc. (OGEN) Income Statement
OGEN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOGEN revenue and net income
OGEN profit margins
OGEN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OGEN quarterly EPS vs estimates
Oragenics beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 6, 2026.
OGEN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $37,653 | $131,521 | $86,987 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $4.1M | $15.5M | $44,667 | $41,237 | $22.1M | $62,622 | $30,110 | $65,803 | $75,044 |
| Gross profit | — | −$4.1M | −$27,391 | $86,854 | $45,750 | −$22.1M | −$62,622 | −$30,110 | −$65,803 | −$75,044 |
| Research & development | $2.39B | $4.1M | $15.5M | $10.1M | $10.6M | $22.1M | $12.1M | $6.0M | $3.5M | $4.8M |
| Sales, general & admin | $6.97B | $6.4M | $5.5M | $4.5M | $5.3M | $4.5M | $3.8M | $4.0M | $3.2M | $3.8M |
| Total operating expenses | $9.4M | $10.6M | $20.9M | $14.4M | $15.8M | $4.5M | $15.9M | $10.0M | $6.7M | $8.5M |
| Operating income | −$9.4M | −$10.6M | −$20.9M | −$14.4M | −$15.8M | −$26.6M | −$15.9M | −$10.0M | −$6.7M | −$8.5M |
| Interest income | $182,229 | $45,897 | $238,759 | $135,900 | $75,847 | $89,294 | $320,011 | $86,527 | $10,221 | $40,090 |
| Interest expense | $785,930 | $29,828 | $30,591 | $15,103 | $15,756 | $10,685 | $7,300 | $5,786 | $216,328 | $4,116 |
| Income before taxes | −$10.0M | −$10.6M | −$20.7M | −$14.3M | −$15.7M | −$26.4M | −$15.6M | −$9.9M | −$6.7M | −$8.5M |
| Income taxes | −$136,910 | — | −$1 | −$127,000 | $16,426 | $12,480 | $7,756 | −$79,999 | $13,207 | −$1.5M |
| Net income | −$9.8M | −$10.6M | −$20.7M | −$14.3M | −$15.7M | −$26.4M | −$15.6M | −$9.9M | −$6.7M | −$7.0M |
| EBITDA | $762.2M | −$10.5M | −$20.6M | −$14.2M | −$15.7M | −$26.6M | −$15.5M | −$9.9M | −$6.4M | −$8.4M |
| EPS (diluted) | −$2.30 | −$1.85 | −$48.80 | −$199.14 | −$217.23 | −$777.07 | −$526.85 | −$1319.95 | −$1.32 | −$721.16 |
| Gross margin | — | — | −72.7% | 66.0% | 52.6% | — | — | — | — | — |
| Operating margin | — | — | −55,519.9% | −10,964.6% | −18,130.3% | — | — | — | — | — |
| Net margin | — | — | −54,858.1% | −10,864.0% | −18,062.0% | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3.1M | $0 | $0 | $0 | $0 | $7,466 |
| Cost of revenue | — | — | — | — | $449,679 | $341,542 | $1.6M | $879,041 | $906,779 | $663,414 | $11.0M | $4,785 |
| Gross profit | — | — | — | — | −$449,679 | −$341,542 | $1.6M | −$879,041 | −$906,779 | −$663,414 | −$11.0M | $2,681 |
| Research & development | $1.2M | $645,470 | $670,543 | $930,894 | $449,679 | $341,542 | $1.7M | $879,041 | $906,779 | $663,414 | $11.0M | $769,350 |
| Sales, general & admin | $1.4M | $1.6M | $1.8M | $2.2M | $1.3M | $1.7M | $1.7M | $1.6M | $1.4M | $1.8M | $1.8M | $1.3M |
| Total operating expenses | $2.6M | $2.3M | $2.5M | $3.1M | $1.7M | $2.0M | $3.4M | $2.4M | $2.3M | $2.5M | $1.8M | $2.1M |
| Operating income | −$2.6M | −$2.3M | −$2.5M | −$3.1M | −$1.7M | −$2.0M | −$3.4M | −$2.4M | −$2.3M | −$2.5M | −$12.8M | −$2.1M |
| Interest income | — | $40,876 | $87,091 | $68,142 | $16,793 | $10,203 | $10,791 | $9,466 | $6,405 | $19,235 | — | $50,613 |
| Interest expense | $414 | $3,727 | $7,454 | $7,039 | $572,310 | $199,127 | $10,969 | $9,971 | $1,803 | $7,085 | $12,231 | $14,170 |
| Income before taxes | −$2.6M | −$2.2M | −$2.4M | −$3.1M | −$2.3M | −$2.2M | −$3.3M | −$2.5M | −$2.3M | −$2.5M | −$12.7M | −$2.0M |
| Income taxes | −$46,377 | −$22,625 | −$136,910 | — | — | — | — | — | −$6,848 | −$6,848 | −$4,121 | $59,288 |
| Net income | −$2.5M | −$2.2M | −$2.3M | −$3.1M | −$2.3M | −$2.2M | −$3.3M | −$2.5M | −$2.3M | −$2.5M | −$12.7M | −$2.0M |
| EBITDA | −$2.6M | −$2.2M | −$2.4M | $64,223 | −$1.7M | −$1.8M | −$3.3M | −$2.5M | −$2.3M | −$2.4M | −$12.7M | −$2.0M |
| EPS (diluted) | −$0.57 | −$0.51 | — | −$1.96 | −$3.10 | −$3.65 | −$0.27 | −$0.38 | −$0.51 | −$0.70 | −$4.14 | −$0.85 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | 35.9% |
| Operating margin | — | — | — | — | — | — | −106.9% | — | — | — | — | −28,053.1% |
| Net margin | — | — | — | — | — | — | −106.7% | — | — | — | — | −26,960.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OGEN's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OGEN financial results
Oragenics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $9.8 million. Diluted earnings per share came to −$2.30.
See the OGEN stock overview for the latest quote and news, or the OGEN chart for price history and technical indicators.
OGEN income statement FAQ
Does Oragenics have revenue?
Oragenics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Oragenics profitable?
No. Oragenics reported a net loss of $9.8 million in fiscal 2025.
How much does Oragenics spend on research and development?
Oragenics spent $2.4 billion on research and development in fiscal 2025.
What are Oragenics's earnings per share?
Oragenics earned $-2.30 per diluted share in fiscal 2025, compared with $-1.85 a year earlier.
When will Oragenics report its next earnings?
Oragenics is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does Oragenics's fiscal year end?
Oragenics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.